Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) Invests More Than $7 Million in C2N Diagnostics’ Blood Tests

New investment supports DxA’s mission to advance the development of scalable and universally accessible diagnostics. Blood tests will be key to further evolving Alzheimer’s diagnostics, care, and research. NEW YORK, Sept. 25, 2024 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation…